|The I-Ap (public; Ia.m57) n/a (Catalog #MBS520364) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The Anti-Mouse I-Ap (public; Ia.m57), Biotin (Clone 7-16.17) (mouse IgG2a) reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s I-Ap (public; Ia.m57) can be used in a range of immunoassay formats including, but not limited to, Immunohistochemistry (IHC). Researchers should empirically determine the suitability of the I-Ap (public; Ia.m57) n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Please refer to the product datasheet for known applications of a given antibody. We\'ve tested the Anti-Mouse I-Ap (public; Ia.m57), Biotin (Clone 7-16.17) (mouse IgG2a) with the following immunoassay(s):
anti-I-Ap monoclonal antibody is a cytotoxic antibody which defines a public I-An antigen. This antibody reacts with I-An antigen from the following I-A haplotypes: I-Ap,k,q,r,s,b. Using recombinant strains, reactivity against the b haplotype has been localized to the Ab subregion. This antibody can be used to quantitate or eliminate I-A bearing cells or for precipitating I-An antigen.
Fusion Partner: SP2/0. Presentation: 100 ug Biotin conjugated Ig buffered in PBS, 0.02% NaN3 and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing I-Ap (public; Ia.m57) are readily searchable from our website. Different antibodies against the same target such as I-Ap (public; Ia.m57) may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.